title: Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
abstract: Apolipoprotein C-III (ApoC-III) regulates lipoprotein and triglyceride (TG) metabolism and may have a causal role in cardiovascular disease. In the Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension (MARINE) and ANCHOR studies, icosapent ethyl, a high-purity prescription eicosapentaenoic acid ethyl ester, reduced TG, and other atherogenic lipid parameters without increasing low-density lipoprotein cholesterol (LDL-C) compared with placebo.
  
  
  
  To evaluate the effects of icosapent ethyl on plasma ApoC-III levels in patients from 2 phase 3 studies.
  
  
  
  MARINE and ANCHOR were 12-week double-blind studies of icosapent ethyl in adult patients. Patients in MARINE had very high TG levels (≥500 and ≤2000 mg/dL) and patients in ANCHOR had high TG levels (≥200 and <500 mg/dL) despite statin control of LDL-C. This post hoc analysis of MARINE and ANCHOR assessed the median percent change from baseline in plasma ApoC-III levels vs placebo and includes subgroup analyses by statin use/efficacy and median ApoC-III levels.
  
  
  
  We assessed ApoC-III levels in 148 and 612 patients in the MARINE and ANCHOR studies, respectively. In MARINE, the approved prescription dose of icosapent ethyl (4 g/day) significantly reduced ApoC-III levels by 25.1% (P < .0001) vs placebo. In ANCHOR, icosapent ethyl 4 g/day significantly reduced ApoC-III levels by 19.2% (P < .0001) vs placebo; subanalysis by statin efficacy revealed significant reductions vs placebo in the higher-efficacy and medium-efficacy groups (24.6% and 17.2%, respectively; both P < .0001).
  
  
  
  Icosapent ethyl 4 g/day significantly reduced plasma ApoC-III levels in patients with elevated TGs from the MARINE and ANCHOR studies.
authors.affiliation: Baylor College of Medicine and the Houston Methodist DeBakey Heart and Vascular Center, Houston, TX, USA. Electronic address: cmb@bcm.tmc.edu.
authors.forename: Christie M
authors.initials: CM
authors.lastname: Ballantyne
authors.affiliation: Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA.
authors.forename: Harold E
authors.initials: HE
authors.lastname: Bays
authors.affiliation: Doylestown, PA, USA.
authors.forename: Rene A
authors.initials: RA
authors.lastname: Braeckman
authors.affiliation: Amarin Pharma Inc., Bedminster, NJ, USA.
authors.forename: Sephy
authors.initials: S
authors.lastname: Philip
authors.affiliation: East Lyme, CT, USA.
authors.forename: William G
authors.initials: WG
authors.lastname: Stirtan
authors.affiliation: Amarin Pharma Inc., Bedminster, NJ, USA.
authors.forename: Ralph T
authors.initials: RT
authors.lastname: Doyle
authors.affiliation: Mystic, CT, USA.
authors.forename: Paresh N
authors.initials: PN
authors.lastname: Soni
authors.affiliation: Amarin Pharma Inc., Bedminster, NJ, USA.
authors.forename: Rebecca A
authors.initials: RA
authors.lastname: Juliano
mesh_terms: D053305:Apolipoprotein C-III / Q000097:blood*; D050197:Atherosclerosis / Q000097:blood; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D053305:Apolipoprotein C-III; D014280:Triglycerides; C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid
keywords: Apolipoprotein C-III; Cardiovascular diseases; Eicosapentaenoic acid; Hypertriglyceridemia; Omega-3 fatty acid; Triglycerides